High-dose cyclophosphamide without stem cell rescue in scleroderma

C. V. Tehlirian, Laura Hummers, B. White, Robert A Brodsky, Fredrick Wigley

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the safety and tolerability of high-dose cyclophosphamide without stem cell rescue in scleroderma. Methods: An open-label, single-site, uncontrolled study design entered patients with active diffuse cutaneous scleroderma. Patients were treated with cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 μg/kg/day). The primary clinical efficacy end point was the modified Rodnan skin score (mRSS). Secondary end points included the Health Assessment Questionnaire-Disability Index (HAQ-DI), physician global assessment (PGA) and pulmonary function tests. Results: Six patients (4 men, 2 women) aged 19-60 years were entered into the study. One patients died early in the protocol, thus five patients had follow-up data. The percentage reduction of the mRSS in these five evaluable patients within 1 month of treatment was 60%, 55%, 41%, 31% and 0%. The patient with no decline in skin score at 1 month showed a decrease in skin score from 41 to 26 by the 3-month visit, a 37% improvement. Three patients sustained the improvement after treatment for 24, 12 and 12 months. Two patients relapsed at 12 and 6 months after treatment. The PGA and HAQ-DI scores improved in five of the six patients by 72% and 79% respectively at 3 months. The only serious adverse event was a death that occurred owing to infection after neutrophil count recovery. Conclusions: High-dose cyclophosphamide without stem cell rescue can lead to a clinically significant improvement in skin score and measures of disease severity in patients with diffuse cutaneous scleroderma.

Original languageEnglish (US)
Pages (from-to)775-781
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume67
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Stem cells
Cyclophosphamide
Skin
Stem Cells
Health
Diffuse Scleroderma
Granulocyte Colony-Stimulating Factor
Labels
Recovery
Physicians
Respiratory Function Tests
Neutrophils
Therapeutics
Safety

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

High-dose cyclophosphamide without stem cell rescue in scleroderma. / Tehlirian, C. V.; Hummers, Laura; White, B.; Brodsky, Robert A; Wigley, Fredrick.

In: Annals of the Rheumatic Diseases, Vol. 67, No. 6, 06.2008, p. 775-781.

Research output: Contribution to journalArticle

@article{dea1f5d7230e4505bd0f7c1eabd106f9,
title = "High-dose cyclophosphamide without stem cell rescue in scleroderma",
abstract = "Objective: To investigate the safety and tolerability of high-dose cyclophosphamide without stem cell rescue in scleroderma. Methods: An open-label, single-site, uncontrolled study design entered patients with active diffuse cutaneous scleroderma. Patients were treated with cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 μg/kg/day). The primary clinical efficacy end point was the modified Rodnan skin score (mRSS). Secondary end points included the Health Assessment Questionnaire-Disability Index (HAQ-DI), physician global assessment (PGA) and pulmonary function tests. Results: Six patients (4 men, 2 women) aged 19-60 years were entered into the study. One patients died early in the protocol, thus five patients had follow-up data. The percentage reduction of the mRSS in these five evaluable patients within 1 month of treatment was 60{\%}, 55{\%}, 41{\%}, 31{\%} and 0{\%}. The patient with no decline in skin score at 1 month showed a decrease in skin score from 41 to 26 by the 3-month visit, a 37{\%} improvement. Three patients sustained the improvement after treatment for 24, 12 and 12 months. Two patients relapsed at 12 and 6 months after treatment. The PGA and HAQ-DI scores improved in five of the six patients by 72{\%} and 79{\%} respectively at 3 months. The only serious adverse event was a death that occurred owing to infection after neutrophil count recovery. Conclusions: High-dose cyclophosphamide without stem cell rescue can lead to a clinically significant improvement in skin score and measures of disease severity in patients with diffuse cutaneous scleroderma.",
author = "Tehlirian, {C. V.} and Laura Hummers and B. White and Brodsky, {Robert A} and Fredrick Wigley",
year = "2008",
month = "6",
doi = "10.1136/ard.2007.077446",
language = "English (US)",
volume = "67",
pages = "775--781",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - High-dose cyclophosphamide without stem cell rescue in scleroderma

AU - Tehlirian, C. V.

AU - Hummers, Laura

AU - White, B.

AU - Brodsky, Robert A

AU - Wigley, Fredrick

PY - 2008/6

Y1 - 2008/6

N2 - Objective: To investigate the safety and tolerability of high-dose cyclophosphamide without stem cell rescue in scleroderma. Methods: An open-label, single-site, uncontrolled study design entered patients with active diffuse cutaneous scleroderma. Patients were treated with cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 μg/kg/day). The primary clinical efficacy end point was the modified Rodnan skin score (mRSS). Secondary end points included the Health Assessment Questionnaire-Disability Index (HAQ-DI), physician global assessment (PGA) and pulmonary function tests. Results: Six patients (4 men, 2 women) aged 19-60 years were entered into the study. One patients died early in the protocol, thus five patients had follow-up data. The percentage reduction of the mRSS in these five evaluable patients within 1 month of treatment was 60%, 55%, 41%, 31% and 0%. The patient with no decline in skin score at 1 month showed a decrease in skin score from 41 to 26 by the 3-month visit, a 37% improvement. Three patients sustained the improvement after treatment for 24, 12 and 12 months. Two patients relapsed at 12 and 6 months after treatment. The PGA and HAQ-DI scores improved in five of the six patients by 72% and 79% respectively at 3 months. The only serious adverse event was a death that occurred owing to infection after neutrophil count recovery. Conclusions: High-dose cyclophosphamide without stem cell rescue can lead to a clinically significant improvement in skin score and measures of disease severity in patients with diffuse cutaneous scleroderma.

AB - Objective: To investigate the safety and tolerability of high-dose cyclophosphamide without stem cell rescue in scleroderma. Methods: An open-label, single-site, uncontrolled study design entered patients with active diffuse cutaneous scleroderma. Patients were treated with cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 μg/kg/day). The primary clinical efficacy end point was the modified Rodnan skin score (mRSS). Secondary end points included the Health Assessment Questionnaire-Disability Index (HAQ-DI), physician global assessment (PGA) and pulmonary function tests. Results: Six patients (4 men, 2 women) aged 19-60 years were entered into the study. One patients died early in the protocol, thus five patients had follow-up data. The percentage reduction of the mRSS in these five evaluable patients within 1 month of treatment was 60%, 55%, 41%, 31% and 0%. The patient with no decline in skin score at 1 month showed a decrease in skin score from 41 to 26 by the 3-month visit, a 37% improvement. Three patients sustained the improvement after treatment for 24, 12 and 12 months. Two patients relapsed at 12 and 6 months after treatment. The PGA and HAQ-DI scores improved in five of the six patients by 72% and 79% respectively at 3 months. The only serious adverse event was a death that occurred owing to infection after neutrophil count recovery. Conclusions: High-dose cyclophosphamide without stem cell rescue can lead to a clinically significant improvement in skin score and measures of disease severity in patients with diffuse cutaneous scleroderma.

UR - http://www.scopus.com/inward/record.url?scp=45149125661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149125661&partnerID=8YFLogxK

U2 - 10.1136/ard.2007.077446

DO - 10.1136/ard.2007.077446

M3 - Article

C2 - 17974598

AN - SCOPUS:45149125661

VL - 67

SP - 775

EP - 781

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -